Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat2 days ago • Google News
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛2 days ago • Google News